{"disease":{"id":"metastatic-neuroendocrine-tumors","name":"metastatic neuroendocrine tumors","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pentetreotide","indication_name":"metastatic neuroendocrine tumors","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Octreoscan","generic_name":"PENTETREOTIDE","company_name":"Sun Pharm Inds Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01174121","title":"Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":332,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT04579757","title":"Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Hutchmed","has_results":true},{"nct_id":"NCT00688623","title":"RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03728361","title":"Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"Dwight Owen","has_results":false},{"nct_id":"NCT06242119","title":"Clinical Application of the J-PET Scanner Prototype","phase":"","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT05556473","title":"F-Tryptophan PET/CT in Human Cancers","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Barbara Ann Karmanos Cancer Institute","has_results":false},{"nct_id":"NCT07404176","title":"Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}